Recursion, Roche, and its Genentech subsidiary have announced plans to co-develop a neuroscience discovery program based on ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Why are we so susceptible to clickbait? Columnist Jacob Aron traces it to a surprising source: a mathematical framework that ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $3.34, demonstrating a +1.21% change from the preceding day's closing price. The stock outpaced the S&P 500's daily gain of 0.38%.

Recursive’s $400 million outlay represents the bulk of the company’s fundraising to date.

Paul Gigot interviews military analyst Seth Jones. Most of us would struggle to imagine a world in which U.S. soldiers, police officers, Border Patrol agents and elected leaders could be dragged ...

During the 1944 Cowra breakout, over 900 prisoners attempted to escape from an Allied camp in Australia. The uprising ...